nipocalimab-aahu (Imaavy)
Jump to navigation
Jump to search
Indications
- treatment of myasthenia gravis with with anti-AChR Ab or anti-MuSK Ab[1][2]
Dosage
- 30 mg/kg loading dose, then 15 mg/kg every 2 weeks
Adverse effects
- headache (14.3%)
- muscle spasms (12.2%)
- COVID-19 (15.3%)
- peripheral edema (11.2%)
Mechanism of action
- blocks IgG binding site on the neonatal Fc receptor
- reduces serum IgG (total), including pathogenic IgG autoantibodies in generalized myasthenia gravis[1]
More general terms
References
- ↑ 1.0 1.1 1.2 George J Nipocalimab Shows Sustained Efficacy in Myasthenia Gravis. Phase III trial met primary endpoint at 6 months. MedPage Today October 16, 2024 https://www.medpagetoday.com/meetingcoverage/aanem/112433
- ↑ 2.0 2.1 George J FDA Approves Nipocalimab for Adult and Pediatric Myasthenia Gravis. FcRn blocker gets green light for patients with anti-AChR or anti-MuSK antibodies. MedPage Today April 30, 2025 https://www.medpagetoday.com/neurology/generalneurology/115356